background
critic
need
effect
therapi
immedi
avail
control
spread
diseas
studi
assess
current
market
intraven
immunoglobulin
ivig
product
antibodi
human
common
coronavirus
may
crossreact
viru
method
gamunex
c
flebogamma
dif
grifol
ivig
test
sever
betacoronavirus
antigen
use
elisa
techniqu
hcov
undetermin
antigen
n
protein
sarscov
cultur
lysat
merscov
n
protein
proteinrbd
protein
protein
result
ivig
product
show
consist
reactiv
compon
test
virus
posit
crossreact
seen
sarscov
merscov
posit
reactiv
observ
ivig
concentr
rang
gamunexc
mgml
flebogamma
dif
conclus
gamunexc
flebogamma
dif
ivig
contain
antibodi
react
antigen
prepar
may
use
immedi
treatment
diseas
outbreak
novel
viral
respiratori
diseas
caus
infect
sever
acut
respiratori
syndrom
sar
coronaviru
due
extrem
transmiss
spread
dramat
within
week
sinc
first
recognit
china
late
decemb
increas
human
mobil
global
phenomenon
creat
favor
condit
becom
pandem
although
symptom
typic
mild
patient
group
progress
sever
respiratori
failur
associ
signific
morbid
mortal
patient
sever
diseas
strain
avail
critic
care
resourc
mostaffect
countri
short
term
lack
vaccin
therapeut
agent
proven
efficaci
aggrav
trend
critic
situat
demand
reliabl
therapi
immedi
avail
control
spread
diseas
convalesc
plasma
plasmaderiv
immunoglobulin
ig
either
polyval
ig
prepar
pool
plasma
thousand
healthi
donor
hyperimmun
ig
prepar
plasma
donor
high
titer
antibodi
specif
antigen
histor
use
fastest
therapeut
option
outbreak
emerg
reemerg
infect
four
main
common
human
coronavirus
identifi
far
thought
human
becom
infect
coronavirus
lifetim
novel
emerg
coronaviru
join
sarscov
respons
sar
outbreak
merscov
respons
middl
east
respiratori
syndrom
mer
outbreak
sinc
coronaviru
infect
induc
virusneutr
antibodi
convalesc
plasma
therapi
success
use
sar
mer
patient
common
human
coronavirus
constantli
circul
around
globe
account
larg
proport
respiratori
infect
case
mild
ubiqu
antibodi
human
common
coronavirus
present
normal
popul
sinc
intraven
ig
ivig
polyval
ig
prepar
plasma
thousand
donor
product
cover
larg
spectrum
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
immun
gener
popul
expect
includ
anticoronavirus
antibodi
import
note
coronavirus
subgroup
particularli
betacoronavirus
sarscov
merscov
show
crossreact
antigen
respons
crossreact
sarscov
merscov
common
human
betacoronavirus
report
neutral
fact
new
betacoronaviru
directli
relat
sarscov
share
sequenc
homolog
suggest
antigen
crossreact
possibl
least
protein
explor
potenti
therapeut
pathway
design
studi
detect
antibodi
common
human
coronavirus
ivig
product
may
crossreact
new
viru
gamunex
c
grifol
therapeut
inc
raleigh
nc
us
flebogamma
dual
inactiv
filtrat
dif
instituto
grifol
sa
barcelona
spain
ivig
test
crossreact
sever
betacoronavirus
includ
sarscov
merscov
antigen
use
elisa
techniqu
gamunexc
flebogamma
dif
highli
purifi
unmodifi
human
ivig
product
manufactur
plasma
collect
donor
us
andor
sever
european
countri
gamunexc
avail
mgml
flebogamma
dif
avail
mgml
mgml
igg
concentr
ivig
manufactur
process
contain
dedic
step
high
viru
clearanc
capac
solventdeterg
sd
treatment
heat
treatment
capryl
treatment
nanofiltr
nm
pore
size
gamunexc
flebogamma
dif
show
consist
reactiv
compon
test
virus
includ
varieti
viru
protein
except
nprotein
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
reactiv
protein
even
undilut
ivig
sampl
tabl
posit
reactiv
particularli
appar
sarscov
merscov
case
merscov
posit
reactiv
observ
ivig
sampl
dilut
n
protein
protein
protein
protein
posit
reactiv
rang
ivig
concentr
gamunexc
mgml
flebogamma
dif
tabl
reactiv
hcov
betacoronaviru
undetermin
antigen
also
observ
although
less
consist
neg
gamunex
posit
flebogamma
dif
low
dilut
tabl
need
readili
avail
effect
therapi
combat
infect
compel
studi
consid
whether
ivig
treatment
could
contribut
diseas
manag
test
hypothesi
known
current
avail
ivig
product
gamunexc
flebogamma
dif
test
crossreact
coronavirus
includ
sarscov
merscov
found
signific
crossreact
compon
test
virus
includ
protein
protein
respons
virion
attach
host
cell
neutral
consist
crossreact
result
among
sarscov
merscov
virus
noteworthi
replic
new
crossreact
alreadi
report
sarscov
merscov
human
betacoronavirus
importantli
gamunexc
flebogamma
dif
confirm
contain
antibodi
react
antigen
could
import
quest
immedi
therapi
elisa
result
undetermin
antigen
hcov
also
mostli
posit
contrast
neg
reactiv
discov
hong
kong
although
result
outbreak
restrict
spread
viru
probabl
still
circul
popul
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
howev
neg
ivig
reaction
use
singl
elisa
coronaviru
kit
mean
ivig
contain
antibodi
pathogen
elisa
sensit
reli
factor
antigen
use
sequenc
organ
use
produc
amount
materi
coat
elisa
result
compar
qualit
sinc
comparison
result
differ
kit
difficult
base
differ
sensit
gold
standard
quantif
addit
scarciti
test
common
coronavirus
observ
patient
develop
sever
clinic
cours
infect
higher
plasma
level
proinflammatori
cytokin
suggest
possibl
cytokin
storm
associ
diseas
sever
ivig
product
demonstr
effect
treatment
inflammatori
disord
date
number
possibl
mechan
immunomodulatori
antiinflammatori
effect
ivig
therapi
describ
includ
anticompl
effect
antiidiotyp
neutral
pathogen
autoantibodi
immun
regul
via
inhibitori
fc
receptor
enhanc
regulatori
cell
inhibit
differenti
thu
ivig
may
mediat
wide
varieti
biolog
immunomodulatori
effect
via
variou
type
blood
cell
altogeth
known
immunomodulatori
effect
ivig
product
could
benefici
diseas
manag
anecdot
case
seri
report
describ
posit
effect
high
dose
ivig
three
patient
note
ivig
product
gener
deem
safe
welltoler
advers
effect
mild
transient
conclus
consist
observ
crossreact
ivig
product
sarscov
merscov
use
elisa
differ
manufactur
evid
support
presenc
crossreact
antibodi
ivig
prepar
result
togeth
known
immun
properti
ivig
suggest
potenti
posit
contribut
current
avail
ivig
product
diseas
manag
step
confirm
function
ivig
antibodi
neutral
studi
warrant
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
